WO2003077864A3 - Methods and compositions for directing cells to target organs - Google Patents

Methods and compositions for directing cells to target organs Download PDF

Info

Publication number
WO2003077864A3
WO2003077864A3 PCT/US2003/007834 US0307834W WO03077864A3 WO 2003077864 A3 WO2003077864 A3 WO 2003077864A3 US 0307834 W US0307834 W US 0307834W WO 03077864 A3 WO03077864 A3 WO 03077864A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mammal
compositions
target organs
directing cells
Prior art date
Application number
PCT/US2003/007834
Other languages
French (fr)
Other versions
WO2003077864A2 (en
Inventor
Catherine A Phillips
Original Assignee
Dep Veterans Affairs Rehab R&D
Catherine A Phillips
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dep Veterans Affairs Rehab R&D, Catherine A Phillips filed Critical Dep Veterans Affairs Rehab R&D
Priority to AU2003225791A priority Critical patent/AU2003225791A1/en
Publication of WO2003077864A2 publication Critical patent/WO2003077864A2/en
Publication of WO2003077864A3 publication Critical patent/WO2003077864A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/51Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.
PCT/US2003/007834 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs WO2003077864A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003225791A AU2003225791A1 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36449802P 2002-03-15 2002-03-15
US60/364,498 2002-03-15

Publications (2)

Publication Number Publication Date
WO2003077864A2 WO2003077864A2 (en) 2003-09-25
WO2003077864A3 true WO2003077864A3 (en) 2004-04-01

Family

ID=28041926

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/007834 WO2003077864A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs
PCT/US2003/007836 WO2003077865A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs
PCT/US2003/007934 WO2003105908A2 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2003/007836 WO2003077865A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs
PCT/US2003/007934 WO2003105908A2 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs

Country Status (10)

Country Link
US (8) US7282222B2 (en)
EP (1) EP1499347A2 (en)
JP (1) JP2006501169A (en)
KR (1) KR20050013531A (en)
CN (1) CN100579577C (en)
AU (4) AU2003225791A1 (en)
CA (1) CA2479309A1 (en)
HK (1) HK1079987A1 (en)
IL (1) IL164079A0 (en)
WO (3) WO2003077864A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
IL156303A0 (en) 2000-12-06 2004-01-04 Robert J Hariri Method of collecting placental stem cells
EP2314673B1 (en) * 2001-02-14 2013-07-24 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP2316463B1 (en) 2001-02-14 2017-04-12 Anthrogenesis Corporation Tissue matrices comprising placental stem cells, and methods of making them
US7700090B2 (en) 2002-02-13 2010-04-20 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
CN100579577C (en) * 2002-03-15 2010-01-13 退伍军人事务研发服务部 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
EP1622645B1 (en) * 2002-04-23 2013-10-23 Roger Williams Hospital Compositions and methods for stem cell delivery
WO2003106640A2 (en) * 2002-06-14 2003-12-24 Case Western Reserve University Cell targeting methods and compositions
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2008121719A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
KR20050062605A (en) * 2002-10-10 2005-06-23 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
KR20100125479A (en) 2002-11-26 2010-11-30 안트로제네시스 코포레이션 Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US20060263336A1 (en) * 2003-03-24 2006-11-23 Caplan Arnold I Cell targeting methods and compositions
AU2004227342B2 (en) * 2003-04-01 2011-01-20 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
AU2005227295A1 (en) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
CA3066594A1 (en) * 2004-10-08 2006-04-20 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
FI20055398A0 (en) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Method for evaluating cell populations
MX343814B (en) 2005-10-13 2016-11-24 Anthrogenesis Corp Immunomodulation using placental stem cells.
PT2471905T (en) 2005-12-29 2019-01-11 Celularity Inc Placental stem cell populations
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
CN103893211A (en) 2006-03-07 2014-07-02 吉塔·什罗夫 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
CA2672998C (en) 2007-01-02 2013-08-06 University Of Central Florida Research Foundation, Inc. Methods and materials for stimulating proliferation of stem cells
FI20075030A0 (en) 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Method of modifying cells
US20090104160A1 (en) * 2007-02-01 2009-04-23 Moraga Biotechnology Corporation Mobilization of Stem Cells After Trauma and Methods Therefor
CN103356711A (en) 2007-02-12 2013-10-23 人类起源公司 Immunomodulation using placental stem cells
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US9119391B1 (en) 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
RU2010109698A (en) * 2007-09-19 2011-09-27 Плуристем Лтд. (Il) ADHESIVE CELLS OF FATTY TISSUE OR PLACENTA AND THEIR USE FOR MEDICAL PURPOSES
ES2719931T3 (en) 2007-09-28 2019-07-16 Celularity Inc Tumor suppression using human placental perfusate and intermediate natural killer cells that come from human placenta
US8142759B2 (en) * 2007-12-12 2012-03-27 Institute Of Nuclear Energy Research Glyco-molecular imaging method for grade classification of liver fibrosis and its glyco-molecular imaging agent thereof
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
CA2723480A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
CA2734237C (en) 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
WO2010021714A2 (en) 2008-08-20 2010-02-25 Anthrogenesis Corporation Improved cell composition and methods of making the same
MX2011001992A (en) 2008-08-22 2011-03-29 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations.
EP3115451A1 (en) 2008-09-02 2017-01-11 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
RU2015130665A (en) 2008-11-19 2018-12-24 Антродженезис Корпорейшн AMNIOTIC ADHESIVE CELLS
US10328103B2 (en) 2009-01-03 2019-06-25 Ray C. Wasielewski Medical treatment composition comprising mammalian dental pulp stem cells
US8470308B2 (en) * 2009-01-03 2013-06-25 Ray C. Wasielewski Enhanced medical implant comprising disrupted tooth pulp and tooth particles
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
KR20120115602A (en) 2010-01-26 2012-10-18 안트로제네시스 코포레이션 Treatment of bone-related cancers using placental stem cells
US20130071361A1 (en) * 2010-02-18 2013-03-21 Sanjeev Gupta Methods of treatment of hemophilia
TWI756797B (en) 2010-04-07 2022-03-01 美商瑟魯勒瑞堤股份有限公司 Angiogenesis using placental stem cells
CN102933221A (en) 2010-04-08 2013-02-13 人类起源公司 Treatment of sarcoidosis using placental stem cells
CA2838694A1 (en) * 2010-06-18 2011-12-22 Women And Infants Hospital Of Rhode Island Lung regeneration using cord blood-derived hematopoietic stem cells
CN103097520B (en) 2010-07-13 2017-12-05 人类起源公司 The method for producing NK
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2012036786A1 (en) 2010-09-17 2012-03-22 University Of L'aquila Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
KR101835917B1 (en) 2011-03-22 2018-03-07 플루리스템 리미티드 Methods for treating radiation or chemical injury
MX357749B (en) 2011-06-01 2018-07-23 Anthrogenesis Corp Treatment of pain using placental stem cells.
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles
CN105079792A (en) * 2014-05-14 2015-11-25 中国科学院上海生命科学研究院 Application of IL-17 in improving mesenchymal stem cell immunity inhibition function
US20170248581A1 (en) * 2014-10-07 2017-08-31 NuTech Medical, Inc. Mesenchymal Stem Cell Diagnostic Testing
EP3356415A1 (en) * 2015-09-29 2018-08-08 Amgen Inc. Asgr inhibitors
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
KR102509006B1 (en) 2017-04-01 2023-03-13 에이브이엠 바이오테크놀로지, 엘엘씨 Replacement of cytotoxic preconditioning prior to cellular immunotherapy
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466951A (en) 1982-11-12 1984-08-21 University Of California Intracellular trapping of therapeutics or tracer agents
JPS61503003A (en) * 1984-04-19 1986-12-25 ユニバ−シテイ− オブ クイ−ンスランド Contraceptive methods, contraceptive preparations and contraceptive devices
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4801533A (en) * 1986-06-25 1989-01-31 Fudenberg H Hugh Method of using alpha-1 acid glycoprotein on T-cells as a marker for alzheimer's disease
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5352432A (en) 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5342607A (en) 1986-07-03 1994-08-30 Advanced Magnetics, Inc. Receptor mediated endocytosis type magnetic resonance imaging contrast agents
DK172391B1 (en) * 1986-12-30 1998-05-18 Nihon Mediphysics Co Ltd High Molecular Compound for Use as a Non-Radioactive Carrier, Radiolabeled High Molecular Compound, Method for Preparation thereof, and Method for Improved Labeling of an Asialoglycoprotein Acceptor Conducting Compound
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5098843A (en) * 1987-06-04 1992-03-24 Calvin Noel M Apparatus for the high efficiency transformation of living cells
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5128257A (en) * 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US4970154A (en) * 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5043260A (en) 1987-11-02 1991-08-27 Rhode Island Hospital Perfusion device with hepatocytes
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
ZA922265B (en) * 1991-03-28 1992-12-30 American Cyanamid Co Somatostatin receptor
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
KR950014915B1 (en) * 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5545130A (en) * 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
CA2134239C (en) 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US5616690A (en) 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
US5322682A (en) 1992-08-06 1994-06-21 The Regents Of The University Of California Method for quantitatively measuring and mapping stored iron in tissue using MRI
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
AU6102494A (en) 1993-02-05 1994-08-29 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
CN1127527A (en) 1993-05-17 1996-07-24 加利福尼亚大学董事会 Ribozyme gene therapy for HIV infection and Aids
US5525503A (en) * 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
US5527884A (en) * 1993-12-21 1996-06-18 President And Fellows Of Harvard College Mediators of chronic allograft rejection and DNA molecules encoding them
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
US5683866A (en) 1996-05-09 1997-11-04 Sarkar; Debi P. Process for producing a targeted gene
WO1998000560A2 (en) * 1996-07-02 1998-01-08 Massachusetts Institute Of Technology Method for determining lymphocyte distribution and trafficking in mammals using imaging
US5719020A (en) * 1996-09-25 1998-02-17 Oklahoma Medical Research Foundation 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens
US7282220B1 (en) * 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
EP2341072A3 (en) 1997-05-08 2013-10-30 Oncothyreon Inc. Method for Generating Activated T-Cells and Antigen-Pulsed Antigen-Presenting Cells
US6466599B1 (en) * 1999-04-07 2002-10-15 Lambda Physik Ag Discharge unit for a high repetition rate excimer or molecular fluorine laser
AU3923000A (en) * 1999-04-16 2000-11-02 Amgen, Inc. Agp-1 fusion protein compositions and methods
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
CN100579577C (en) * 2002-03-15 2010-01-13 退伍军人事务研发服务部 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
KR20050062605A (en) * 2002-10-10 2005-06-23 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOHELER K. ET AL.: "Can exogenous stem cells be used in transplantation?", CELLS, TISSUES, ORGANS, vol. 165, 1999, pages 237 - 245, XP002955728 *
COSSET F. ET AL.: "Targeting retrovirus entry", GENE THERAPY, vol. 3, no. 11, 1996, pages 946 - 956, XP000613590 *
GAO J. ET AL.: "The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion", CELLS, TISSUES, ORGANS, vol. 169, 2001, pages 12 - 20, XP002972733 *
GARDINER J. ET AL.: "The therapeutic potential of synthetic multivalent carbohydrates", EXPERTS OPINION ON INVESTIGATIONAL DRUGS, vol. 7, no. 3, 1998, pages 405 - 411, XP002922337 *
MUCHITSCH E. ET AL.: "Effects of human alpha-1-acid glycoprotein on aminonucleoside-induced minimal change nephrosis in rats", NEPHRON, vol. 81, no. 2, 1999, pages 194 - 199, XP002972734 *

Also Published As

Publication number Publication date
WO2003105908A2 (en) 2003-12-24
US20070248577A1 (en) 2007-10-25
AU2003225791A8 (en) 2003-09-29
AU2003225791A1 (en) 2003-09-29
US7282222B2 (en) 2007-10-16
AU2003225793A1 (en) 2003-09-29
CN1649621A (en) 2005-08-03
US20060171934A1 (en) 2006-08-03
US7563459B2 (en) 2009-07-21
WO2003077865A3 (en) 2004-04-01
US20100047215A1 (en) 2010-02-25
US20070243175A1 (en) 2007-10-18
KR20050013531A (en) 2005-02-04
AU2003267949A1 (en) 2003-12-31
CA2479309A1 (en) 2003-12-24
AU2009201808A1 (en) 2009-05-28
EP1499347A2 (en) 2005-01-26
WO2003105908A3 (en) 2004-10-28
CN100579577C (en) 2010-01-13
US20070110734A9 (en) 2007-05-17
WO2003105908B1 (en) 2004-12-16
WO2003077864A2 (en) 2003-09-25
WO2003077865A2 (en) 2003-09-25
US20070243174A1 (en) 2007-10-18
US20040180040A1 (en) 2004-09-16
US20070243173A1 (en) 2007-10-18
JP2006501169A (en) 2006-01-12
AU2003225793A8 (en) 2003-09-29
US20070196331A1 (en) 2007-08-23
HK1079987A1 (en) 2006-04-21
IL164079A0 (en) 2005-12-18
WO2003105908A9 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
WO2003077864A3 (en) Methods and compositions for directing cells to target organs
NO20035637L (en) Carbon monoxide improves the results of tissue and organ transplants and suppresses apoptosis
WO2001078754A3 (en) Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
WO2004098535A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2007064846A3 (en) COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION
WO2004101758A3 (en) Composition for maintaining organ and cell viability
WO2002098897A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
IL206293A0 (en) Genetically engineered duckweed
EP1638460A4 (en) Directing cells to target tissues or organs
WO2006010070A3 (en) Compositions and methods related to peptides that selectively bind leukemia cells
WO2007016501A3 (en) Compositions and method for brain specific targeted delivery of therapeutic agents
AU2003304250A1 (en) Method of isolating cells from umbilical cord
WO2006074012A3 (en) Facilitated cellular reconstitution of organs and tissues
NZ551828A (en) A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
WO2004006833A3 (en) Bowel cleansing composition
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
GB2415698A (en) Transformation of brassica
MXPA02002444A (en) Method for generating immune compatible cells and tissues using nuclear transfer techniques.
WO2005001044A3 (en) Compositions related to pleiotrophin methods and uses thereof
WO2001060983A3 (en) Treatment for bone disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP